EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction

Emily C Hanselman iD, Caroline P Harmon iD, Daiyong Deng, Sarah M Sywanycz, Lauren Caronia, Peihua Jiang, Paul A S Breslin iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Emily C Hanselman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Ibuprofen, Receptors, G-Protein-Coupled, Taste, Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCD NIH HHS, NIH HHS, National Institute on Deafness and Other Communication Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The human sweet taste receptor, TAS1R2–TAS1R3, conveys sweet taste in the mouth and may help regulate glucose metabolism throughout the body. Ibuprofen and naproxen are structurally similar to known inhibitors of TAS1R2–TAS1R3 and have been associated with metabolic benefits. Here, we determined if ibuprofen and naproxen inhibited TAS1R2–TAS1R3 responses to sugars in vitro and their elicited sweet taste in vivo, in humans under normal physiological conditions, with implications for effects on glucose metabolism. Experimental Approach Human psychophysical taste testing and in vitro cellular calcium assays in HEK293 cells were performed to determine the effects of ibuprofen and naproxen on sugar taste signalling. Key Results Ibuprofen and naproxen inhibited the sweet taste of sugars and non‐nutritive sweeteners in humans, dose‐dependently. Ibuprofen reduced cellular signalling of sucrose and sucralose in vitro with heterologously expressed human TAS1R2 (hTAS1R2)–TAS1R3 in human kidney cells. To mirror internal physiology, low concentrations of ibuprofen, which represent human plasma levels after a typical dose, inhibit the sweet taste and oral detection of glucose at concentrations nearing post‐prandial plasma glucose levels. Conclusion and Implications Ibuprofen and naproxen inhibit activation of TAS1R2–TAS1R3 by sugar in humans. Long‐term ibuprofen intake is associated with preserved metabolic function and reduced risk of metabolic diseases such as Alzheimer's, diabetes and colon cancer. In addition to its anti‐inflammatory properties, we present here a novel pathway that could help explain the associations between metabolic function and chronic ibuprofen use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IbuprofenReceptors, G-Protein-CoupledTasteGlucoseHumansHEK293 CellsNaproxenMaleAdultFemaleSweetening AgentsYoung AdultAnti-Inflammatory Agents, Non-Steroidal

Stichwörter der Autor:innen

TAS1R2–TAS1R3fructosenaproxenplasma glucosesucralosesucrosesweetness inhibitiontaste

Substanzen

IbuprofenReceptors, G-Protein-CoupledGlucoseNaproxentaste receptors, type 1Sweetening AgentsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey, USA.
  • Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Emily C Hanselman, Caroline P Harmon, Paul A S Breslin

Förderung

  • NIDCD NIH HHS
  • NIH HHS
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Hanselman, E. C., Harmon, C. P., Deng, D., Sywanycz, S. M., Caronia, L., Jiang, P., & Breslin, P. A. S. (2025). Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction. British Journal of Pharmacology. https://doi.org/10.1111/bph.70004

Vancouver

Hanselman EC, Harmon CP, Deng D, Sywanycz SM, Caronia L, Jiang P, et al. Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction. British Journal of Pharmacology. 2025. doi:10.1111/bph.70004

BibTeX
@article{Hanselman2025,
  author = {Hanselman, Emily C and Harmon, Caroline P and Deng, Daiyong and Sywanycz, Sarah M and Caronia, Lauren and Jiang, Peihua and Breslin, Paul A S},
  title = {Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70004}
}
Kostenlos starten →